These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 36264105)
1. Screening of marine natural products for potential inhibitors targeting biotin biosynthesis pathway in Alamri MA; Ahmad S; Alqahtani SM; Irfan M; Alabbas AB; Tahir Ul Qamar M J Biomol Struct Dyn; 2023; 41(17):8535-8543. PubMed ID: 36264105 [TBL] [Abstract][Full Text] [Related]
2. The Biotin Biosynthetic Pathway in Mycobacterium tuberculosis is a Validated Target for the Development of Antibacterial Agents. Bockman MR; Mishra N; Aldrich CC Curr Med Chem; 2020; 27(25):4194-4232. PubMed ID: 30663561 [TBL] [Abstract][Full Text] [Related]
3. Virtual screening to identify novel potential inhibitors for Glutamine synthetase of Kumari M; Subbarao N J Biomol Struct Dyn; 2020 Oct; 38(17):5062-5080. PubMed ID: 31755360 [TBL] [Abstract][Full Text] [Related]
4. Structure-based discovery of phenyl-diketo acids derivatives as Shukla R; Shukla H; Tripathi T J Biomol Struct Dyn; 2021 May; 39(8):2945-2958. PubMed ID: 32306850 [No Abstract] [Full Text] [Related]
5. Structure-Based Optimization of Pyridoxal 5'-Phosphate-Dependent Transaminase Enzyme (BioA) Inhibitors that Target Biotin Biosynthesis in Mycobacterium tuberculosis. Liu F; Dawadi S; Maize KM; Dai R; Park SW; Schnappinger D; Finzel BC; Aldrich CC J Med Chem; 2017 Jul; 60(13):5507-5520. PubMed ID: 28594172 [TBL] [Abstract][Full Text] [Related]
8. Identification of new benzamide inhibitor against α-subunit of tryptophan synthase from Mycobacterium tuberculosis through structure-based virtual screening, anti-tuberculosis activity and molecular dynamics simulations. Naz S; Farooq U; Ali S; Sarwar R; Khan S; Abagyan R J Biomol Struct Dyn; 2019 Mar; 37(4):1043-1053. PubMed ID: 29502488 [TBL] [Abstract][Full Text] [Related]
9. Structure-based virtual screening, molecular dynamics simulation and MM-PBSA toward identifying the inhibitors for two-component regulatory system protein NarL of Kumar N; Srivastava R; Prakash A; Lynn AM J Biomol Struct Dyn; 2020 Jul; 38(11):3396-3410. PubMed ID: 31422761 [TBL] [Abstract][Full Text] [Related]
10. Identification of Singh S; Khare G; Bahal RK; Ghosh PC; Tyagi AK Drug Des Devel Ther; 2018; 12():1065-1079. PubMed ID: 29750019 [TBL] [Abstract][Full Text] [Related]
11. Pharmacophore model-based virtual screening, docking, biological evaluation and molecular dynamics simulations for inhibitors discovery against Naz S; Farooq U; Khan S; Sarwar R; Mabkhot YN; Saeed M; Alsayari A; Muhsinah AB; Ul-Haq Z J Biomol Struct Dyn; 2021 Feb; 39(2):610-620. PubMed ID: 31937192 [TBL] [Abstract][Full Text] [Related]
12. Identification of novel multitarget antitubercular inhibitors against mycobacterial peptidoglycan biosynthetic Mur enzymes by structure-based virtual screening. Kumari M; Subbarao N J Biomol Struct Dyn; 2022 Nov; 40(18):8185-8196. PubMed ID: 33826470 [TBL] [Abstract][Full Text] [Related]
13. Target-based identification of whole-cell active inhibitors of biotin biosynthesis in Mycobacterium tuberculosis. Park SW; Casalena DE; Wilson DJ; Dai R; Nag PP; Liu F; Boyce JP; Bittker JA; Schreiber SL; Finzel BC; Schnappinger D; Aldrich CC Chem Biol; 2015 Jan; 22(1):76-86. PubMed ID: 25556942 [TBL] [Abstract][Full Text] [Related]
14. Exploring the interaction mechanism between potential inhibitor and multi-target Mur enzymes of mycobacterium tuberculosis using molecular docking, molecular dynamics simulation, principal component analysis, free energy landscape, dynamic cross-correlation matrices, vector movements, and binding free energy calculation. Kumari M; Singh R; Subbarao N J Biomol Struct Dyn; 2022; 40(24):13497-13526. PubMed ID: 34662260 [TBL] [Abstract][Full Text] [Related]
16. Anti-tubercular Modelling via QSAR Approach, In Silico Design and Virtual Docking Screening of Designed Hypothetical Inhibitors Against DNA gyrase Protein. Adeniji SE Curr Comput Aided Drug Des; 2021; 17(6):739-758. PubMed ID: 32586260 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of Chouhan M; Tiwari PK; Moustafa M; Chaubey KK; Gupta A; Kumar R; Sahoo AK; Azhar EI; Dwivedi VD; Kumar S J Biomol Struct Dyn; 2024; 42(2):948-959. PubMed ID: 37139795 [TBL] [Abstract][Full Text] [Related]
18. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship. Tomioka H Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755 [TBL] [Abstract][Full Text] [Related]
19. Copper transporter protein (MctB) as a therapeutic target to elicit antimycobacterial activity against tuberculosis. Dwivedi M; Jose S; Gupta M; Devi SS; Raj R; Kumar D J Biomol Struct Dyn; 2024 Jul; 42(10):5334-5348. PubMed ID: 37340670 [TBL] [Abstract][Full Text] [Related]
20. Natural phytocompounds physalin D, withaferin a and withanone target L-asparaginase of Sharma D; Saini R; Mishra A J Biomol Struct Dyn; 2023 Apr; 41(7):2645-2659. PubMed ID: 35132949 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]